Iparomlimab + tuvonralimab is under clinical development by Qilu Puget Sound Biotherapeutics and currently in Phase I for Gastroesophageal (GE) Junction Carcinomas. According to GlobalData, Phase I drugs for Gastroesophageal (GE) Junction Carcinomas have an 85% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Iparomlimab + tuvonralimab’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Iparomlimab + tuvonralimab overview

Tuvonralimab (PSB-205) in combination with iparomlimab is under development for the treatment of relapsed/refractory malignant solid tumors including squamous and non-squamous non-small cell lung cancer (NSCLC), recurrent or metastatic cervical cancer, nasopharyngeal carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma, locally advanced or metastatic gastric or gastroesophageal carcinoma, colon carcinoma, small cell lung cancer, kidney cancer (renal cell cancer), liver cancer, endometrial cancer, transitional cell cancer (urothelial cell cancer), advanced urothelial cancer, metastatic colorectal cancer, metastatic melanoma, soft tissue sarcoma, bone sarcoma, metastatic renal cell carcinoma. The drug candidate is a bi-specific antibody product that contains a mixture of unique anti-PD-1 and anti-CTLA4 monoclonal antibodies produced by a single cell line via the company's proprietary MabPair technology. It is administered through intravenous drip and subcutaneous route. It is being developed based on MabPair antibody technology platform.

Qilu Puget Sound Biotherapeutics overview

Qilu Puget Sound Biotherapeutics (Sound Biologics) is a biotech company. The company develops treatments for cancer.

For a complete picture of Iparomlimab + tuvonralimab’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.